Swedish drug development company in clinical phase focused on normalizing the lives for patients with Sickle Cell Disease.
Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.
An orphan disease with large unmet medical need.
Modus colleagues presented our story at the 5th Annual Sickle Cell Disease Therapeutics conference in New York in October
Learn more about our study in the Middle East
Sankt Eriksgatan 117,
SE-113 43 Stockholm, Sweden
© 2017 Modus Therapeutics. | All Rights Reserved.